Morphogenesis Receives FDA Fast Track Designation

Morphogenesis Receives FDA Fast Track Designation

MORPHOGENESIS RECEIVES FDA FAST TRACK DESIGNATION FOR ITS CANCER IMMUNOTHERAPY CANDIDATE IFX-HU2.0 

 Tampa, FL, April 08, 2021 – Morphogenesis, Inc. (“Morphogenesis”), a clinical stage biotechnology company specializing in the development of cell and gene therapy products to treat chronic diseases such as cancer, announced today that the United States Food and Drug Administration (FDA) has granted the Company’s lead clinical stage candidate, IFx-Hu2.0, Fast Track drug designation for the treatment of patients with advanced skin cancer. Specifically, these are patients with unresectable or metastatic cutaneous melanoma who have not responded to, or have stopped responding to, FDA-approved immune checkpoint inhibitors. Most advanced skin cancer patients who receive immune checkpoint inhibitors do not respond to these therapies. Based on the data amassed to date and its mechanism of action, IFx-Hu2.0 has the potential to change that. The FDA previously granted Orphan Drug Designation to IFx-Hu2.0 for the same indication.

Fast Track is a designation issued by the FDA for products that have the potential to treat patients with a serious disease and who have an unmet medical need. Morphogenesis provided the FDA with epidemiologic data as well as pre-clinical and clinical evidence to support IFx-Hu2.0’s mechanism of action. IFx-Hu2.0 is an immunomodulator that as well as initiating a significant anti-tumor response in previously untreated patients, also has the potential to re-sensitize patients to immune checkpoint inhibitors. More people have skin cancer than all the other primary cancers in the United States combined. Advanced melanoma’s aggressiveness and high mortality rate make it the deadliest type of skin cancer.

“We believe that being able to initiate a broad anti-tumor response in late-stage melanoma patients with a 30-second intralesional injection of IFx-Hu2.0 fulfills an unmet medical need of these patients,” said Patricia D. Lawman, PhD, Chief Executive Officer of Morphogenesis.

“Fast Track designation for IFx-Hu2.0 signifies the FDA’s recognition that patients suffering from this life-threatening disease remain in dire need of effective treatment options even with all the therapies that are being developed for melanoma. IFx-Hu2.0 holds promise to effectively treat these patients,” said Michael J.P. Lawman, PhD, President of Morphogenesis.

The FDA is committed to facilitating the development and to expediting the review of IFx-Hu2.0 to treat patients with advanced skin cancer, thereby potentially addressing a significant unmet medical need. Morphogenesis is advancing the clinical development of IFx-Hu2.0, a highly differentiated cancer immunotherapy drug candidate, especially since IFx-Hu2.0 is now eligible for accelerated approval and priority review if relevant criteria are met.

“With IFx-Hu2.0’s Fast Track designation, we look forward to having expert guidance and frequent communication with the FDA throughout the entire drug development and review process,” said Christopher Konig, PharmD, Regulatory Affairs Manager at Morphogenesis. “In the past, this quality and frequency of communication with the FDA has led to earlier drug approval and access by patients.”

About Morphogenesis, Inc.: Morphogenesis, Inc. is a clinical stage biotechnology company developing novel cell and gene therapies with initial focus on skin cancers such as cutaneous melanoma, cutaneous squamous cell carcinoma and Merkel cell carcinoma. The Company is leveraging its proprietary immunotherapy ImmuneFx platform comprised of gene therapy-based, off-the-shelf immunomodulators that induce personalized, multivalent, systemic, and sustained immune responses. Its lead candidate is IFx-Hu2.0, an immunotherapeutic consisting of pAc/emm55, a plasmid DNA (pDNA).

For Investor Inquiries: Westwicke, an ICR Company; Stephanie Carrington, Managing Director, [email protected]; (646) 277-1282

For Media Inquiries: Cesar R. Hernandez Founder + Managing Director 434 West 33rd Street 7th to 13th Floors, New York, NY 10001 400 N Tampa St. 15th floor - Tampa, FL 33620 M: (813) 277-6540 W: omnipublic.global